RESUMEN
PURPOSE: Kabuki syndrome (KS) (OMIM 147920 and 300867) is a rare genetic disorder characterized by specific facial features, intellectual disability, and various malformations. Immunopathological manifestations seem prevalent and increase the morbimortality. To assess the frequency and severity of the manifestations, we measured the prevalence of immunopathological manifestations as well as genotype-phenotype correlations in KS individuals from a registry. METHODS: Data were for 177 KS individuals with KDM6A or KMT2D pathogenic variants. Questionnaires to clinicians were used to assess the presence of immunodeficiency and autoimmune diseases both on a clinical and biological basis. RESULTS: Overall, 44.1% (78/177) and 58.2% (46/79) of KS individuals exhibited infection susceptibility and hypogammaglobulinemia, respectively; 13.6% (24/177) had autoimmune disease (AID; 25.6% [11/43] in adults), 5.6% (10/177) with ≥2 AID manifestations. The most frequent AID manifestations were immune thrombocytopenic purpura (7.3% [13/177]) and autoimmune hemolytic anemia (4.0% [7/177]). Among nonhematological manifestations, vitiligo was frequent. Immune thrombocytopenic purpura was frequent with missense versus other types of variants (p = 0.027). CONCLUSION: The high prevalence of immunopathological manifestations in KS demonstrates the importance of systematic screening and efficient preventive management of these treatable and sometimes life-threatening conditions.
Asunto(s)
Enfermedades Autoinmunes/epidemiología , Proteínas de Unión al ADN/genética , Cara/anomalías , Enfermedades Hematológicas/complicaciones , Histona Demetilasas/genética , Proteínas de Neoplasias/genética , Enfermedades de Inmunodeficiencia Primaria/epidemiología , Enfermedades Vestibulares/complicaciones , Anomalías Múltiples/genética , Anomalías Múltiples/inmunología , Adolescente , Adulto , Anciano , Niño , Preescolar , Femenino , Estudios de Asociación Genética , Enfermedades Hematológicas/genética , Enfermedades Hematológicas/inmunología , Humanos , Lactante , Recién Nacido , Masculino , Persona de Mediana Edad , Mutación , Prevalencia , Sistema de Registros , Índice de Severidad de la Enfermedad , Enfermedades Vestibulares/genética , Enfermedades Vestibulares/inmunología , Adulto JovenRESUMEN
Biallelic germline pathogenic variants in one of the four mismatch repair genes (MSH2, MSH6, MLH1 and PMS2) cause a very rare, highly penetrant, childhood-onset cancer syndrome, called constitutional mismatch repair deficiency (CMMRD). The European consortium "Care for CMMRD" (C4CMMRD) was founded in Paris in 2013 to facilitate international collaboration and improve our knowledge of this rare cancer predisposition syndrome. Following initial publications on diagnostic criteria and surveillance guidelines for CMMRD, several partners collaborating within the C4CMMRD consortium have worked on and published numerous CMMRD-related clinical and biological projects. Since its formation, the C4CMMRD consortium held meetings every 1-2 years (except in 2020 and 2021 due to the Covid 19 pandemic). The sixth C4CMMRD meeting was held in Paris in November 2022, and brought together 42 participants from nine countries involved in various fields of CMMRD healthcare. The aim was to update members on the latest results and developments from ongoing research, and to discuss and initiate new study proposals. As previously done for the fifth meeting of the C4CMMRD group, this report summarizes data presented at this meeting.
Asunto(s)
Síndromes Neoplásicos Hereditarios , Humanos , Síndromes Neoplásicos Hereditarios/genética , Síndromes Neoplásicos Hereditarios/diagnóstico , Síndromes Neoplásicos Hereditarios/terapia , Proteína 2 Homóloga a MutS/genética , Homólogo 1 de la Proteína MutL/genética , Paris , Endonucleasa PMS2 de Reparación del Emparejamiento Incorrecto/genética , Proteínas de Unión al ADN/genética , Neoplasias Encefálicas/genética , Neoplasias Encefálicas/terapia , Mutación de Línea Germinal , Europa (Continente) , Neoplasias ColorrectalesRESUMEN
The association of a germline mutation in the BRCA1/2 genes in breast cancer leads to a higher genomic instability and, thus, a potential higher sensitivity to poly(ADP-ribose) polymerase (PARP) inhibitors. In this review, we will summarize the different DNA-repair pathways including PARP-dependent mechanisms that support the use of PARP inhibitors. We will present clinical trials evaluating PARP inhibitors alone or in combination in early or advanced stage breast cancer. We will then discuss the different mechanisms involved in the resistance to PARP inhibitors. We will also introduce the concept of BRCAness by which the use of PARP inhibitors could be extended to BRCA1/2-wild type patients. Finally, we will describe the new channels implemented for the theranostic genetic screening.